Phathom Pharmaceuticals, Inc.
PHAT
$13.50
-$0.69-4.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 202.74% | 439.36% | 1,391.58% | 4,249.56% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.74% | 439.36% | 1,391.58% | 4,249.56% | -- |
| Cost of Revenue | 162.73% | 266.13% | 774.18% | 2,184.43% | -- |
| Gross Profit | 209.47% | 479.44% | 1,568.57% | 4,919.22% | -- |
| SG&A Expenses | -32.25% | 12.44% | 52.35% | 34.54% | 225.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.67% | 17.49% | 49.42% | 26.25% | 144.39% |
| Operating Income | 78.43% | 22.48% | -12.74% | 14.97% | -98.54% |
| Income Before Tax | 64.98% | 17.10% | -13.84% | 6.43% | -97.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.98% | 17.10% | -13.84% | 6.43% | -97.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.98% | 17.10% | -13.84% | 6.43% | -97.90% |
| EBIT | 78.43% | 22.48% | -12.74% | 14.97% | -98.54% |
| EBITDA | 78.59% | 22.50% | -12.83% | 15.02% | -98.67% |
| EPS Basic | 69.16% | 33.01% | 7.67% | 24.55% | -73.87% |
| Normalized Basic EPS | 69.16% | 33.01% | 7.67% | 24.54% | -73.87% |
| EPS Diluted | 69.16% | 33.01% | 7.67% | 24.55% | -73.87% |
| Normalized Diluted EPS | 69.16% | 33.01% | 7.67% | 24.54% | -73.87% |
| Average Basic Shares Outstanding | 13.57% | 23.75% | 23.30% | 24.00% | 13.82% |
| Average Diluted Shares Outstanding | 13.57% | 23.75% | 23.30% | 24.00% | 13.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |